---
slug: melanotan-ii
title: "melanotan ii"
kind: standard
status: published
hash: e1ef545a74b69af70bee321ead92417519f694c5f729d91ad083431f79600493
created: 2026-06-29T17:07:16.799Z
updated: 2026-10-08T11:49:39.974Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# melanotan ii

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T17:07:19.610Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?](https://pubmed.ncbi.nlm.nih.gov/40210573/) — “The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported. ... Histological analysis confirmed the diagnosis of a mucosal malignant melanoma.” (sha256 6b1e3402fed6775a)
2. [Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo](https://www.trialx.com/clinical-trials/listings/337033/melanotan-ii-mt-ii-as/) — “This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo. ... Recruiting” (sha256 3dfe111cab09b1bf)
3. [Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use](https://www.sciencedirect.com/science/article/pii/S2352512626002766) — “Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. ... Melanotan I primarily targets MC1R, whereas melanotan II is a nonselective agonist with broader systemic effects” (sha256 beb7386780d78bca)